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Table S1. Strains used in this study. 
Strain Genotype Source Figure 
YL515 [BY4741/2] MATα; his3∆1, leu2∆0, ura3∆0 [1] 1A-F 
MB27 [YL515] gtr1∆::HIS3 [1] 1A-F, 2C 
MB28 [YL515] gtr2∆::HIS3 [1] 1A-F, 2C 
NP52-2A [YL515] ego2∆::kanMX This study 1A-F 
NP44 [YL515] ego4∆::kanMX This study 1A-F 
NP51-3C [YL515] ego2∆::kanMX, gtr1∆::kanMX This study 1A, C- D, F, 2C 
NP54-4D [YL515] ego2∆::kanMX, gtr2∆::kanMX This study 1A, C- D, F, 2C 
NP48-5C [YL515] ego4∆::kanMX, gtr1∆::kanMX This study 1A, C- D, F, 2C 
NP60-10D [YL515] ego4∆::kanMX, gtr2∆::kanMX This study 1A, C- D, F, 2C 
KT1961 MATa; trp1, leu2, his3, ura3-52 [2] 5C-D 
CDV213 [KT1961] EGO1-GFP::TRP1 [3] 2A 
CDV221-1A [KT1961] ego3∆::natMX, EGO1-GFP::TRP1 This study 2A 
KP12-1C [KT1961] ego2∆::kanMX, EGO1-GFP::TRP1 This study 2A, 3B 
KP37-4B [KT1961] ego2∆::kanMX, ego3∆::natMX EGO1-GFP::TRP1 This study 2A 
KP22-2C [KT1961] ego4∆::kanMX, EGO1-GFP::TRP1 This study 2A, 3B 
CDV214 [KT1961] EGO3-GFP::TRP1 [3] 2A 
CDV219-4A [KT1961] ego1∆::natMX, EGO3-GFP::TRP1 This study 2A, 5B 
KP13-2D [KT1961] ego2∆::kanMX, EGO3-GFP::TRP1 This study 2A, 3B 
KP39-6D [KT1961] ego2∆::kanMX, ego1∆::natMX, EGO3-GFP::TRP1 This study 2A 
KP35-2D [KT1961] ego4∆::kanMX, EGO3-GFP::TRP1 This study 2A, 3B 
CDV210 [KT1960] ego1∆::natMX [3] 2B, 5C-D 
KP27-5A [KT1961] ego1∆::natMX, ego2∆::kanMX This study 2B, 3F, 5B 
KP33-3C [KT1961] ego1∆::natMX, ego4∆::kanMX This study 2B 
MP268-2B [KT1961] gtr1∆::natMX, gtr2∆::natMX This study 2D-E, 5C-D, 6A-C 
KP29-3B [KT1961] gtr1∆::natMX, gtr1∆::natMX, ego2∆::kanMX This study 2D-E, 3F 
KP34-1A [KT1961] gtr1∆::natMX, gtr1∆::natMX, ego4∆::kanMX This study 2D-E 
NMY51 MATa; his3Δ200, trp1-901, leu2-3,112, ade2, LYS2::(lexAop)4-
HIS3, ura3::(lexAop)8- lacZ, ade2::(lexAop)8-ADE2, GAL4 
Dualsystems 3A, 5A 
FLJ1 [NMY51] ego3∆::kanMX [4] 3G 
KP12-2D [KT1961] ego2∆::kanMX This study 3E-F 
KP02 [KT1961] ego4∆::kanMX This study 3E-F 
KP28-3D [KT1961] ego2∆::kanMX, ego3∆::natMX This study 3F 
MP279-18B [KT1960] gtr1∆::natMX, ego1∆::kanMX This study 5B 
MP279-18A [KT1961] gtr2∆::natMX, ego1∆::kanMX This study 5B 
KP41-9C  [KT1961] gtr1∆::natMX, gtr2∆::natMX, ego1∆::kanMX, 
ego2∆::kanMX, ego3∆::kanMX (egoc∆) 
This study 6A-C 
KP41-10C [KT1961] gtr1∆::natMX, ego1∆::kanMX, ego2∆::kanMX, 
ego3∆::kanMX 
This study 6D-E 
 
  
Table S2. Plasmids used in this study. 
Plasmid Genotype Source Figure 
pRS413 CEN, HIS3 [5] 1A, D-F, 2A-E, 5B-D 
pRS414 CEN, TRP1 [5] 3E-F, 5B-D 
pRS415 CEN, LEU2 [5] 1A-C, 2A-B, D-E, 3B, E-F, 
5B-D 
pRS416 CEN, URA3 [5] 1A-F, 2A, C, 3B, E-F, 5B-D 
pJU1064 [pRS413] SCH9T570A-HA5 [6] 1B-C, 5D 
pJU1058 [pRS415] SCH9T570A-HA5 [6] 1D-E 
YCplac111 CEN, LEU2 [7]  
pNP2529 [YCplac111] ADH1p-EGO2 This study 1C 
pNP2530 [YCplac111] ADH1p-EGO4 This study 1C 
YCplac33 CEN, URA3 [7]  
pMB1394 [YCplac33] TetON-GTR1Q65L [1] 1D-E 
pMB1395 [YCplac33] TetON-GTR1S20L [1] 1D-E 
pPM1619 [YCplac33] TetON-GTR2Q66L This study 1D-E 
pPM1620 [YCplac33] TetON-GTR2S23L This study 1D-E 
pJU650 [pRS416] GTR1 [4] 1F, 2D-E 
pJU653 [pRS416] GTR1Q65L [1] 1F 
pJU652 [pRS416] GTR1S20L [1] 1F 
pJU651 [pRS416] GTR2 [1] 1F 
pJU655 [pRS416] GTR2Q66L [1] 1F 
pJU654 [pRS416] GTR2S23L [1] 1F 
pFLJ1973 [YCplac33] EGO1-GST This study 2B 
pNP2572 [pRS416] ADH1p-EGO1-TAP This study 2B 
pMP1639 [pRS415] GTR1-GFP [1] 2C, 5B 
pMP1642 [pRS415] GTR2-GFP [1] 2C, 5B 
pMP1640 [pRS415] GTR1Q65L-GFP This study 2C 
pMP1644 [pRS415] GTR2S23L-GFP This study 2C 
pNP2441 [pRS413] EGO2-GFP This study 3E-F, 5B 
pNP2442 [pRS413] EGO4-GFP This study 3E-F, 5B 
pMB1344 [YCplac33] GTR1-TAP [1] 2D-E 
pMB1371 [YCplac33] GTR1S20L-TAP [1] 2E 
pMB1372 [YCplac33] GTR1Q65L-TAP [1] 2E 
pMP2177 [pRS414] GTR2-V5-6HIS [4] 2D-E 
pAI-Alg5 2µ, ADH1-HA-NUB1, TRP1 Dualsystems 3A, G, 5A 
pDL2-Alg5 2µ, ADH1-HA-NUBG, TRP1 Dualsystems 3A, G, 5A 
pCabWT CEN, CYC1-CUB-LexA, LEU2 Dualsystems 3A, G, 5A 
pFLJ2393 [pCabWT] CYC1-EGO2-CUB-LexA This study 3A, G, 5A 
pFLJ2394 [pCabWT] CYC1-EGO4-CUB-LexA This study 3A, G 
pPR3-N 2µ, CYC1-NUBG-HA, TRP1 Dualsystems 3A, G 
pNP1689 [pPR3-N] CYC1-NUBG-HA-GTR1 [1] 3A, G 
pNP1690 [pPR3-N] CYC1-NUBG-HA-GTR1S20L [1] 3A, G 
pNP1691 [pPR3-N] CYC1-NUBG-HA-GTR1Q65L [1] 3A, G 
pNP1692 [pPR3-N] CYC1-NUBG-HA-GTR2 This study 3A, G 
pNP1693 [pPR3-N] CYC1-NUBG-HA-GTR2S23L This study 3A, G 
pNP1694 [pPR3-N] CYC1-NUBG-HA-GTR2Q66L [4] 3A, G 
pNP1696 [pPR3-N] CYC1-NUBG-HA-EGO1 [1] 3A, G, 5A 
Table S2. Plasmids used in this study - continued 
Plasmid Genotype Source Figure 
pMPG2221 [pPR3-N] CYC1-NUBG-HA-EGO3 [4] 3A, G, 5A 
pKP2623 [pRS413] EGO2-HA3 This study 3B 
pKP2622 [pRS413] EGO4-HA3 This study 3B 
pET-15b PT7lac, HIS6, lacI, ApR Novagen  
pNP2564 [pET-15b] HIS6-EGO1, EGO2, EGO3, EGO4 This study 3C-D 
pFLJ2220 [pCabWT] CYC1-EGO3-CUB-LexA [4] 5A 
pFLJ2734 [pPR3-N] CYC1-NUBG-HA-EGO1∆152-184 This study 5A 
pFLJ2735 [pPR3-N] CYC1-NUBG-HA-EGO1∆169-184 This study 5A 
pKP2736 [YCplac33] EGO1-HA3  This study 5B-C 
pKP2737 [YCplac33] EGO1∆152-184-HA3  This study 5B-C 
pKP2738 [YCplac33] EGO1∆169-184-HA3  This study 5B-C 
pKP2739 [YCplac33] EGO1  This study 5C-D 
pKP2740 [YCplac33] EGO1∆152-184 This study 5C-D 
pKP2741 [YCplac33] EGO1∆169-184 This study 5C-D 
pKP2801 [YCplac33] EGO1NT-vhhGFP4 This study 6A-D 
pNSlm-vhhGFP4 pcDNA3-NSlmb-vhhGFP4 [8]  
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Figure S1. TAP pull-down experiments showing that the reduced interaction between Gtr1-TAP and 
Gtr2-V5 in an ego2∆ strain can be rescued by re-introduction of EGO2 expressed from a plasmid. 
Lysates from cells expressing the indicated fusion proteins (input) and TAP pull-down fractions were 
analyzed by immunoblotting with anti-TAP and anti-V5 antibodies. Cells expressing untagged Gtr1 
























Figure S2. In vitro functional analyses of the Ego1-Ego2-Ego3 ternary complex (EGO-TC). (A) 
Analysis of the oligomeric state of the Ego proteins in solution by size-exclusion chromatography. 
The Ego1-Ego2 complex was purified in a similar way as the Ego1-Ego2-Ego3 complex as described 
in the experimental procedures. The Ego1, Ego2, and Ego3 proteins were fused with a C-terminal 
His6-tag. Absorbance at 280 nm is plotted against the elution volume. Positions of the molecular 
weight standards are indicated. (B) In vitro GST-pull down binding assays of GST-fused Ego2, Ego3, 
or Ego4 with full-length or truncated Ego1 and/or Ego2 and Ego3. The results were visualized by 
Coomassie blue staining on SDS-PAGE. (C) In vitro GST-pull down binding assays of GST-fused 
wild-type or mutant Ego2 with Ego1 and Ego3. The results were visualized by Coomassie blue 
staining on SDS-PAGE. (D) SDS-PAGE of the purified EGO-TC used in the crystallization (S1) and 
the protein sample obtained from the crystallization solution (S2). The N-terminal region of Ego1 was 
degraded in the crystallization solution. The loaded proteins were visualized by Coomassie blue 
staining. Molecular weight markers are indicated on the left.  
 
 
Figure S3. Structural comparisons of the Ego proteins and several representative Roadblock domain-
containing proteins. (A) Superposition of Ego2 (colored in yellow) and LAMTOR5 (colored in 
wheat). (B) Superposition of the Ego3 monomer in the EGO-TC (colored in green), LAMTOR2 
(PDB code 3CPT, colored in blue) and LAMTOR3 (PDB code 3CPT, colored in cyan). (C) 
Superposition of the Ego3 monomer in the EGO-TC (colored in green) and the Ego3 homodimer 
(PDB code 4FTX, one monomer colored in orange and the other in gray). (D) Superposition of Ego2 
(colored in yellow) and Ego3 (colored in green) in the EGO-TC with the Ego3 homodimer showing 
that the position for Ego2 binding was occupied by the other monomer in the Ego3 homodimer. (E) 
Superposition of the EGO-TC with Drosophila melanogaster dynein intermediate chain and light 
chain complex (PDB code 3L9K). Ego1, Ego2 and Ego3 of the EGO-TC are colored in pink, yellow 
and green, respectively, and the dynein intermediate chain and light chain are colored in purple and 
skyblue, respectively. 
  
